Preclinical evaluation of a diabody-based 177Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model
详细信息 查看全文
- 作者：Tobias Webera ; 1 ; Benedikt Bö ; ttichera ; 1 ; Michaela A.E. Arndta ; b ; Walter Mierc ; Max Sauterc ; d ; Evelyn Exnera ; Armin Kellera ; Susanne Krä ; merc ; Karin Leottac ; Artjom Wischnjowc ; Ludger Grosse-Hoveste ; Dirk Strumbergf ; Dirk Jä ; gera ; Hermann-Josef Grö ; neg ; Uwe Haberkornc ; d ; Gottfried Bremh ; Jü ; rgen Kraussa ; juergen.krauss@nct-heidelberg.de" class="auth_mail" title="E-mail the corresponding author
- 关键词：CD22 ; Diabody ; Lymphoma ; Radioimmunotherapy ; Dual-targeting ; PEGylation
- 刊名：Cancer Letters
- 出版年：2016
- 出版时间：28 October 2016
- 年：2016
- 卷：381
- 期：2
- 页码：296-304
- 全文大小：2198 K
文摘
- •
A humanized anti-CD22 diabody was purified from transgenic rabbit milk.
- •
The diabody was conjugated to the short-range β-emitter lutetium-177 (177Lu).
- •
Size-optimization of the diabody achieved improved pharmacokinetic properties
- •
177Lu-diabody showed high anti-tumor activity in mice with disseminated lymphoma.
- •
The diabody RIC may have potential for the treatment of patients with B-NHL.